What MannKind Corporation told the SEC could break it.

MannKind manufactures its dry-powder inhalation products (Afrezza and the Tyvaso DPI it makes for United Therapeutics) at a single specialized facility in Danbury, CT (sold and leased back from Creative Manufacturing Properties in 2021). It warns the facilities and specialized manufacturing equipment used to make these products would be costly to replace and could require substantial lead-time to repair or replace. A fire, equipment failure, natural disaster or regulatory shutdown at the single Danbury site would halt the bulk of its product supply — and the royalty stream from UT's Tyvaso DPI — with no rapid backup. A genuine single-facility manufacturing concentration.

“The facilities and the specialized manufacturing equipment used to manufacture these products would be costly to replace and could require substantial lead-time to repair or replace.”

The American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap — previously limited to 100% of a drug's average manufacturer price (AMP) — for single-source and innovator multiple-source drugs, effective January 1, 2024. Because Afrezza is a single-source branded drug, MannKind can now owe Medicaid rebates that exceed the product's AMP (i.e., pay more in rebate than the price), compressing net realized price on Medicaid utilization. Combined with broader drug-pricing-transparency and reimbursement-reform pressure on HHS/CMS, this is a specific, named federal pricing exposure on its commercial franchise. A bounded but specific drug-pricing policy risk.

“eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug's average manufacturer price”